Navigation Links
Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Date:3/3/2009

RICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at two investor conferences during the month of March.

  • Barclays Capital Global Healthcare Conference at 3:45 pm ET, on Tuesday, March 10, 2009
  • Cowen and Company 29th Annual Health Care Conference at 8:00 am ET, on Wednesday, March 18, 2009

The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
3. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
4. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
7. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... WARSAW, Ind. , Aug. 7, 2017 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the third quarter of 2017. ... will be paid on or about October 27, 2017 to ... September 22, 2017.  Future declarations of dividends are subject to ...
(Date:8/7/2017)... 2017  Endo International plc (NASDAQ: ENDP ... virtually all known U.S. mesh product liability claims and ... known remaining U.S. claims at reasonable values. Under the ... fourth quarter of 2017 and continuing through the fourth ... 2017 results, the Company intends to increase its mesh ...
Breaking Medicine Technology:
(Date:8/23/2017)... The Woodlands, Texas (PRWEB) , ... August 23, 2017 , ... ... the leading denied claims firms in Texas. Founded by Bill Voss, the firm grew ... over a decade and a half of helping clients get the money they deserve ...
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the Workgroup ... of health IT to create efficiencies in healthcare information exchange and a trusted advisor ... Summer Forum which featured keynote addresses by Donald W. Rucker, MD, head of ...
(Date:8/23/2017)... , ... August 23, 2017 , ... The Stevie® Awards have announced the winners of ... , the world’s premier business awards competition. , Nominees in the 2017 IBAs were not ... a points system based on the total number of awards won in the IBAs with ...
(Date:8/23/2017)... FL (PRWEB) , ... August 23, 2017 , ... ... for traveling medical professionals, recently launched a new website, http://www.cirrusmedicalstaffing.com . The ... to respond to the needs of healthcare professionals who are traveling on short-term ...
(Date:8/23/2017)... ... August 23, 2017 , ... MobilityWorks ®, the ... to the 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. ... 139 percent, marking the twelfth year that the company has been included on ...
Breaking Medicine News(10 mins):